Table 1.
Demographic, clinical and procedural characteristics of patients undergoing early (<24 h) or delayed invasive treatment strategy (>24 h after hospitalisation)
| All | Treatment strategy | p-value | ||
|---|---|---|---|---|
| Early | Delayed | |||
| n (%) | 1,805 | 972 (53.9) | 833 (46.1) | – |
| Time admission-angiography min (median Q1–3) | 1,330 (360–3,457) | 406 (209–940) | 4,008 (2,436–6,723) | – |
| Demographics | ||||
| Male gender (%) | 68.1 | 69.1 | 67.0 | 0.352 |
| Age (years; mean, SD) | 66.8 (12.1) | 65.0 (12.2) | 68.9 (11.7) | <0.001 |
| Medical history (%) | ||||
| Diabetes | 20.6 | 16.8 | 25.2 | <0.001 |
| Smoking | 31.0 | 33.2 | 28.5 | 0.032 |
| Hypercholesterolaemia | 34.1 | 33.2 | 35.2 | 0.366 |
| Positive family history | 38.4 | 40.6 | 35.8 | 0.035 |
| Previous MI | 17.2 | 13.9 | 21.1 | <0.001 |
| Previous PCI | 18.0 | 14.5 | 22.0 | <0.001 |
| Previous CABG | 12.4 | 9.4 | 15.8 | <0.001 |
| Previous CVA | 3.6 | 2.8 | 4.5 | 0.060 |
| Hypertension | 55.0 | 50.3 | 60.4 | <0.001 |
| Admission parameters | ||||
| Elevated cardiac enzymes (%) | 93.8 | 92.6 | 95.2 | 0.023 |
| GRACE risk score >140a (%) | 37.0 | 32.5 | 42.1 | <0.001 |
| ST segment deviation >0.5 mm (%) | 42.4 | 47.6 | 36.4 | <0.001 |
| CK-max < 24 (umol/l; median, SD) | 168 (100–347) | 190 (108–425) | 146 (92–250) | <0.001 |
| GRACE scorea (median, Q1–3) | 130 (109–155) | 126 (105–150) | 135 (112–163) | <0.001 |
| Killip class > 1 (%) | 27.7 | 26.4 | 29.2 | 0.175 |
| Creatinine > median (%) | 51.0 | 47.7 | 54.9 | 0.003 |
| Vessel disease (%) | <0.001 | |||
| 0 | 11.6 | 9.3 | 14.2 | – |
| 1 | 30.4 | 33.2 | 27.2 | – |
| >1 | 58.0 | 57.5 | 58.6 | – |
| Treatment | <0.001 | |||
| Conservative (%) | 22.6 | 17.7 | 28.5 | – |
| CABG performed (%) | 18.2 | 18.0 | 18.5 | – |
| PCI performed (%) | 59.2 | 64.3 | 53.1 | – |
| Hospitalisation weekend (%) | 26.3 | 23.0 | 30.2 | 0.001 |
| Medication before angiography | ||||
| ASA (%) | 81.2 | 85.3 | 76.4 | <0.001 |
| Clopidogrel (%) | 88.6 | 91.9 | 85.0 | 0.488 |
| G2b3a inhibitor (%) | 16.9 | 22.1 | 10.9 | <0.001 |
| Heparin (%) | 63.7 | 68.9 | 57.7 | <0.001 |
| At discharge (%) | ||||
| ACE-I (%) | 59.0 | 60.6 | 57.2 | 0.159 |
| AII blockers (%) | 11.8 | 9.3 | 14.6 | 0.001 |
| RAS inhibitionb (%) | 70.7 | 70.8 | 70.6 | 0.926 |
| ASA (%) | 83.1 | 86.2 | 79.6 | <0.001 |
| Beta blockers (%) | 91.3 | 91.1 | 91.6 | 0.742 |
| Calcium antagonist (%) | 20.8 | 17.1 | 25.0 | <0.001 |
| P2Y12 inhibitor (%) | 70.7 | 72.6 | 68.5 | 0.055 |
| Coumarin (%) | 17.5 | 12.1 | 23.5 | <0.001 |
| Nitrate (%) | 18.0 | 12.3 | 24.5 | <0.001 |
| Statin (%) | 85.0 | 85.1 | 84.8 | 0.842 |
AII angiotensin II, ACE-I angiotensin converting enzyme inhibitor, ASA acetylsalicylic acid, CABG coronary arterial bypass grafting, CK creatine kinase, CVA cerebrovascular accident, GRACE Global Registry of Acute Coronary Events, MI myocardial infarction, PTCA percutaneous transluminal coronary angioplasty, Q quartile, RAS renin angiotensin system, SD standard deviation
aBased on less than 90% of patients
bACE-I and/or AII blockers